Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Female
Humans
Hyperthermic Intraperitoneal Chemotherapy
Quality of Life
Hyperthermia, Induced
/ methods
Ovarian Neoplasms
/ drug therapy
Carcinoma, Ovarian Epithelial
/ surgery
Combined Modality Therapy
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cytoreduction Surgical Procedures
/ methods
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
23
02
2023
accepted:
04
06
2023
medline:
11
8
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
ppublish
Résumé
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality that aims to target the main site of tumor dissemination in ovarian cancer, the peritoneum, by combining the benefits of intraperitoneal chemotherapy with the synergistic effects of hyperthermia all during a single administration at the time of cytoreductive surgery. High-quality evidence currently only supports the use of HIPEC with cisplatin at the time of interval cytoreduction after neoadjuvant chemotherapy for stage III epithelial ovarian cancer. Many questions remain, including HIPEC's role at other timepoints in ovarian cancer treatment, who are optimal candidates, and specifics of HIPEC protocols. This article reviews the history of normothermic and hyperthermic intraperitoneal chemotherapy in ovarian cancer and evidence regarding HIPEC implementation and patient outcomes. Additionally, this review explores details of HIPEC technique and perioperative care, cost considerations, complication and quality of life data, disparities in HIPEC use, and unresolved issues.
Identifiants
pubmed: 37358686
doi: 10.1245/s10434-023-13757-0
pii: 10.1245/s10434-023-13757-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
5597-5609Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Cancer Stat Facts: Ovarian Cancer: National Cancer Institiute. Surveillance, Epidemiology, and End Results Program. Available at: https://seer.cancer.gov/statfacts/html/ovary.html .
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672–705. https://doi.org/10.1093/annonc/mdz062 . (Epub 2019/05/03).
doi: 10.1093/annonc/mdz062
pubmed: 31046081
Armstrong DK AR, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuk A, Chen LM, Chitiyo V, Cristea M, Derosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Gisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Robertson S, Rodabaugh K, Schorge J, Stewart D, Thaker PH, Vargas R, Wahner Hendrickson A, Werner TL, Zsiros E. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 5.2022.
Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT. High-volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. Pharmacologic basis and early results. Cancer Chemother Pharmacol. 1978;1(3):161–6. https://doi.org/10.1007/bf00253116 . (Epub 1978/01/01).
doi: 10.1007/bf00253116
pubmed: 373916
Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989;49(12):3380–4 (Epub 1989/06/15).
pubmed: 2720692
Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990;25(6):389–94. https://doi.org/10.1007/bf00686048 . (Epub 1990/01/01).
doi: 10.1007/bf00686048
pubmed: 2311166
van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34(1):148–54. https://doi.org/10.1016/s0959-8049(97)00370-5 . (Epub 1998/06/13).
doi: 10.1016/s0959-8049(97)00370-5
pubmed: 9624250
Howell SB, Zimm S, Markman M, Abramson IS, Cleary S, Lucas WE, Weiss RJ. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol. 1987;5(10):1607–12. https://doi.org/10.1200/jco.1987.5.10.1607 . (Epub 1987/10/01).
doi: 10.1200/jco.1987.5.10.1607
pubmed: 2443622
Kirmani S, Lucas WE, Kim S, Goel R, McVey L, Morris J, Howell SB. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma. J Clin Oncol. 1991;9(4):649–57. https://doi.org/10.1200/jco.1991.9.4.649 . (Epub 1991/04/01).
doi: 10.1200/jco.1991.9.4.649
pubmed: 2066761
Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335(26):1950–5. https://doi.org/10.1056/nejm199612263352603 . (Epub 1996/12/26).
doi: 10.1056/nejm199612263352603
pubmed: 8960474
Armstrong DK, Walker JL. Role of intraperitoneal therapy in the initial management of ovarian cancer. J Clin Oncol. 2019;37(27):2416–9. https://doi.org/10.1200/jco.19.00671 . (Epub 2019/08/14).
doi: 10.1200/jco.19.00671
pubmed: 31403863
Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001–7. https://doi.org/10.1200/jco.2001.19.4.1001 . (Epub 2001/02/22).
doi: 10.1200/jco.2001.19.4.1001
pubmed: 11181662
Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43. https://doi.org/10.1056/NEJMoa052985 . (Epub 2006/01/06).
doi: 10.1056/NEJMoa052985
pubmed: 16394300
National Institutes of Health: Clinical advisory: NCI issues clinical announcement for preferred method of treatment for advanced ovarian cancer. Available from: https://www.nlm.nih.gov/databases/alerts/ovarian_ip_chemo.html .
Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;2011(11):CD005340. https://doi.org/10.1002/14651858.CD005340.pub3 . (Epub 2011/11/11).
doi: 10.1002/14651858.CD005340.pub3
Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, Monk BJ, Chan JK. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460–6. https://doi.org/10.1200/jco.2014.55.9898 . (Epub 2015/03/25) are found at the end of this article.
Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Alvarez Secord A, Rubin SC, Mannel RS. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019;37(16):1380–90. https://doi.org/10.1200/jco.18.01568 . (Epub 2019/04/20).
doi: 10.1200/jco.18.01568
pubmed: 31002578
pmcid: 6544459
Fujiwara K, Nagao S, Yamamoto K, Tanabe H, Okamoto A, Takehara K, Saito M, Fujiwara H, Tan D, Adachi S, Yamaguchi S, Kikuchi A, Hirasawa T, Yokoi T, Nagai T, Satoh T, Kamiura S, Fujishita A, Chan K, Sykes P, Olawaiye A, Ryu S-Y, Wong WL, Matsumoto T, Hasegawa K, Enomoto T. A randomized phase 3 trial of intraperitoneal versus intravenous carboplatin with dose-dense weekly paclitaxel in patients with ovarian, fallopian tube, or primary peritoneal carcinoma (a GOTIC-001/JGOG-3019/GCIG, iPocc Trial) (LBA 3). Gynecol Oncol. 2022;166:S49–50. https://doi.org/10.1016/S0090-8258(22)01296-3 .
doi: 10.1016/S0090-8258(22)01296-3
Provencher DM, Gallagher CJ, Parulekar WR, Ledermann JA, Armstrong DK, Brundage M, Gourley C, Romero I, Gonzalez-Martin A, Feeney M, Bessette P, Hall M, Weberpals JI, Hall G, Lau SK, Gauthier P, Fung-Kee-Fung M, Eisenhauer EA, Winch C, Tu D, MacKay HJ. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Ann Oncol. 2018;29(2):431–8. https://doi.org/10.1093/annonc/mdx754 . (Epub 2017/12/01).
doi: 10.1093/annonc/mdx754
pubmed: 29186319
Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100(1):27–32. https://doi.org/10.1016/j.ygyno.2005.11.013 . (Epub 2005/12/22).
doi: 10.1016/j.ygyno.2005.11.013
pubmed: 16368440
Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2015;33(26):2841–7. https://doi.org/10.1200/jco.2015.61.4776 . (Epub 2015/08/05) online at www.jco.org . Author contributions are found at the end of this article.
Ahmed K, Tabuchi Y, Kondo T. Hyperthermia: an effective strategy to induce apoptosis in cancer cells. Apoptosis. 2015;20(11):1411–9. https://doi.org/10.1007/s10495-015-1168-3 . (Epub 2015/09/12).
doi: 10.1007/s10495-015-1168-3
pubmed: 26354715
Los G, Smals OA, van Vugt MJ, van der Vlist M, den Engelse L, McVie JG, Pinedo HM. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res. 1992;52(5):1252–8 (Epub 1992/03/01).
pubmed: 1737387
Oei AL, Vriend LE, Crezee J, Franken NA, Krawczyk PM. Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol. 2015;10:165. https://doi.org/10.1186/s13014-015-0462-0 . (Epub 2015/08/08).
doi: 10.1186/s13014-015-0462-0
pubmed: 26245485
pmcid: 4554295
Chen T, Guo J, Han C, Yang M, Cao X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol. 2009;182(3):1449–59. https://doi.org/10.4049/jimmunol.182.3.1449 . (Epub 2009/01/22).
doi: 10.4049/jimmunol.182.3.1449
pubmed: 19155492
Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, Odijk H, Zelensky A, van Bree C, Stalpers LJ, Buist MR, Soullié T, Rens J, Verhagen HJ, O’Connor MJ, Franken NA, Ten Hagen TL, Kanaar R, Aten JA. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci U S A. 2011;108(24):9851–6. https://doi.org/10.1073/pnas.1101053108 . (Epub 2011/05/11).
doi: 10.1073/pnas.1101053108
pubmed: 21555554
pmcid: 3116433
Cowan RA, O’Cearbhaill RE, Zivanovic O, Chi DS. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. Int J Hyperth. 2017;33(5):548–53. https://doi.org/10.1080/02656736.2017.1283066 . (Epub 2017/01/18).
doi: 10.1080/02656736.2017.1283066
Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570–5. https://doi.org/10.1245/s10434-014-4157-9 . (Epub 2014/11/14).
doi: 10.1245/s10434-014-4157-9
pubmed: 25391263
Dellinger TH, Han ES. State of the science: the role of HIPEC in the treatment of ovarian cancer. Gynecol Oncol. 2021;160(2):364–8. https://doi.org/10.1016/j.ygyno.2020.12.029 . (Epub 2021/01/10).
doi: 10.1016/j.ygyno.2020.12.029
pubmed: 33419611
Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, Grisham RN, Brown AK, Nerenstone S, Diaz JP, Schroeder ED, Langstraat CL, Paroder V, Lakhman Y, Soldan K, Su K, Gardner GJ, Andikyan V, Guo J, Jewell EL, Long Roche K, Troso-Sandoval T, Lichtman SM, Moukarzel LA, Dessources K, Abu-Rustum NR, Aghajanian C, Tew WP, Beumer J, Sonoda Y, O'Cearbhaill RE. Secondary Cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study. J Clin Oncol. 2021;39(23):2594–604. https://doi.org/10.1200/jco.21.00605 . (Epub 2021/05/22).
van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh I, van der Velden J, Arts HJ, Massuger L, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618 . (Epub 2018/01/18).
doi: 10.1056/NEJMoa1708618
pubmed: 29342393
Charo LM, Jou J, Binder P, Hohmann SF, Saenz C, McHale M, Eskander RN, Plaxe S. Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States. Gynecol Oncol. 2020;159(3):681–6. https://doi.org/10.1016/j.ygyno.2020.09.022 . (Epub 2020/09/27).
doi: 10.1016/j.ygyno.2020.09.022
pubmed: 32977989
Antonio CCP, Alida GG, Elena GG, Rocío GS, Jerónimo MG, Luis ARJ, Aníbal ND, Francisco BV, Jesús G, Pablo RR, José GM. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial. Ann Surg Oncol. 2022;29(4):2617–25. https://doi.org/10.1245/s10434-021-11087-7 . (Epub 2021/11/24).
doi: 10.1245/s10434-021-11087-7
pubmed: 34812982
Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg. 2022;157(5):374–83. https://doi.org/10.1001/jamasurg.2022.0143 . (Epub 2022/03/10).
Bhatt A, de Hingh I, Van Der Speeten K, Hubner M, Deraco M, Bakrin N, Villeneuve L, Kusamura S, Glehen O. HIPEC methodology and regimens: the need for an expert consensus. Ann Surg Oncol. 2021;28(13):9098–113. https://doi.org/10.1245/s10434-021-10193-w . (Epub 2021/06/19).
doi: 10.1245/s10434-021-10193-w
pubmed: 34142293
Hübner M, Kusamura S, Villeneuve L, Al-Niaimi A, Alyami M, Balonov K, Bell J, Bristow R, Guiral DC, Fagotti A, Falcão LFR, Glehen O, Lambert L, Mack L, Muenster T, Piso P, Pocard M, Rau B, Sgarbura O, Somashekhar SP, Wadhwa A, Altman A, Fawcett W, Veerapong J, Nelson G. Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) Society Recommendations—Part I: Preoperative and intraoperative management. Eur J Surg Oncol. 2020;46(12):2292–310. https://doi.org/10.1016/j.ejso.2020.07.041 . (Epub 2020/09/03).
doi: 10.1016/j.ejso.2020.07.041
pubmed: 32873454
Hübner M, Kusamura S, Villeneuve L, Al-Niaimi A, Alyami M, Balonov K, Bell J, Bristow R, Guiral DC, Fagotti A, Falcão LFR, Glehen O, Lambert L, Mack L, Muenster T, Piso P, Pocard M, Rau B, Sgarbura O, Somashekhar SP, Wadhwa A, Altman A, Fawcett W, Veerapong J, Nelson G. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) Society Recommendations—Part II: Postoperative management and special considerations. Eur J Surg Oncol. 2020;46(12):2311–23. https://doi.org/10.1016/j.ejso.2020.08.006 . (Epub 2020/08/23).
doi: 10.1016/j.ejso.2020.08.006
pubmed: 32826114
van Stein RM, Lok CAR, Aalbers AGJ, de Hingh IH, Houwink API, Stoevelaar HJ, Sonke GS, van Driel WJ. Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus. Gynecol Oncol Rep. 2022;39:100945. https://doi.org/10.1016/j.gore.2022.100945 . (Epub 2022/03/08).
doi: 10.1016/j.gore.2022.100945
pubmed: 35252523
pmcid: 8894234
Mogal HD, Levine EA, Fino NF, Obiora C, Shen P, Stewart JH, Votanopoulos KI. Routine admission to intensive care unit after cytoreductive surgery and heated intraperitoneal chemotherapy: not always a requirement. Ann Surg Oncol. 2016;23(5):1486–95. https://doi.org/10.1245/s10434-015-4963-8 . (Epub 2015/11/18).
doi: 10.1245/s10434-015-4963-8
pubmed: 26572753
Bouchard-Fortier G, Cusimano MC, Fazelzad R, Sajewycz K, Lu L, Espin-Garcia O, May T, Bouchard-Fortier A, Ferguson SE. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2020;158(1):218–28. https://doi.org/10.1016/j.ygyno.2020.03.034 . (Epub 2020/05/11).
doi: 10.1016/j.ygyno.2020.03.034
pubmed: 32387131
Carboni F, Valle M, Vaira M, Sammartino P, Federici O, Robella M, Deraco M, Framarini M, Macrì A, Sassaroli C, Lippolis PV, Di Giorgio A, Biacchi D, Martin-Roman L, Sperduti I, Baratti D. Complications and mortality rate of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: Italian peritoneal surface malignancies oncoteam results analysis. Cancers (Basel). 2022. https://doi.org/10.3390/cancers14235824 . (Epub 2022/12/12).
doi: 10.3390/cancers14235824
pubmed: 36612274
pmcid: 9818987
Chambers LM, Yao M, Morton M, Gruner M, Chichura A, Horowitz M, Costales AB, Rose PG, Michener CM, Debernardo R. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Gynecol Oncol. 2021;161(2):389–95. https://doi.org/10.1016/j.ygyno.2021.01.039 . (Epub 2021/02/09).
doi: 10.1016/j.ygyno.2021.01.039
pubmed: 33551202
Schwartz PB, Stahl CC, Vande Walle KA, Pokrzywa CJ, Cherney Stafford LM, Aiken T, Barrett J, Acher AW, Leverson G, Ronnekleiv-Kelly S, Weber SM, Abbott DE. What drives high costs of cytoreductive surgery and HIPEC: patient, provider or tumor? Ann Surg Oncol. 2020;27(13):4920–8. https://doi.org/10.1245/s10434-020-08583-7 . (Epub 2020/05/18).
doi: 10.1245/s10434-020-08583-7
pubmed: 32415351
pmcid: 7666650
Behbakht K, Cohn DE, Straughn JM Jr. Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer. Gynecol Oncol. 2018;151(1):4–5. https://doi.org/10.1016/j.ygyno.2018.07.019 . (Epub 2018/08/03).
doi: 10.1016/j.ygyno.2018.07.019
pubmed: 30068488
Koole SN, van Lieshout C, van Driel WJ, van Schagen E, Sikorska K, Kieffer JM, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, Massuger L, Aalbers AG, Verwaal VJ, Van de Vijver KK, Aaronson NK, van Tinteren H, Sonke GS, van Harten WH, Retèl VP. Cost Effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial. J Clin Oncol. 2019;37(23):2041–50. https://doi.org/10.1200/jco.19.00594 . (Epub 2019/06/30).
doi: 10.1200/jco.19.00594
pubmed: 31251694
Lim SL, Havrilesky LJ, Habib AS, Secord AA. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. Gynecol Oncol. 2019;153(2):376–80. https://doi.org/10.1016/j.ygyno.2019.01.025 . (Epub 2019/02/06).
doi: 10.1016/j.ygyno.2019.01.025
pubmed: 30718126
Mattei LH, Robb L, Banning K, Polan RM, Cote ML. Enrollment of individuals from racial and ethnic minority groups in gynecologic cancer precision oncology trials. Obstet Gynecol. 2022. https://doi.org/10.1097/aog.0000000000004917 . (Epub 2022/09/09).
doi: 10.1097/aog.0000000000004917
pubmed: 36075065
pmcid: 8830705
Mishkin G, Minasian LM, Kohn EC, Noone AM, Temkin SM. The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies. Gynecol Oncol. 2016;143(3):611–6. https://doi.org/10.1016/j.ygyno.2016.09.026 . (Epub 2016/10/05).
doi: 10.1016/j.ygyno.2016.09.026
pubmed: 27697287
Hildebrand JS, Wallace K, Graybill WS, Kelemen LE. Racial disparities in treatment and survival from ovarian cancer. Cancer Epidemiol. 2019;58:77–82. https://doi.org/10.1016/j.canep.2018.11.010 . (Epub 2018/12/12).
doi: 10.1016/j.canep.2018.11.010
pubmed: 30528360
Huffman DL, Jayakrishnan TT, Shankar K, Peterson CE, Wegner RE. Disparities in ovarian cancer treatment and overall survival according to race: an update. Gynecol Oncol. 2021;162(3):674–8. https://doi.org/10.1016/j.ygyno.2021.07.011 . (Epub 2021/07/16).
doi: 10.1016/j.ygyno.2021.07.011
pubmed: 34261593
Ulmer KK, Greteman B, Cardillo N, Schneider A, McDonald M, Bender D, Goodheart MJ, Bosquet JG. Disparity of ovarian cancer survival between urban and rural settings. Int J Gynecol Cancer. 2022;32(4):540–6. https://doi.org/10.1136/ijgc-2021-003096 . (Epub 2022/02/25).
doi: 10.1136/ijgc-2021-003096
pubmed: 35197327
pmcid: 8995817
Frost AS, Smith AJB, Fader AN, Wethington SL. Modifiable risk factors associated with long-term survival in women with serous ovarian cancer: a National Cancer Database study. Int J Gynecol Cancer. 2022;32(6):769–80. https://doi.org/10.1136/ijgc-2021-003323 . (Epub 2022/04/24).
doi: 10.1136/ijgc-2021-003323
pubmed: 35459709
Fairfield KM, Murray K, LaChance JA, Wierman HR, Earle CC, Trimble EL, Warren JL. Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer. Gynecol Oncol. 2014;134(3):473–7. https://doi.org/10.1016/j.ygyno.2014.06.011 . (Epub 2014/06/22).
doi: 10.1016/j.ygyno.2014.06.011
pubmed: 24952367